Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment

This study has been completed.
Sponsor:
Information provided by:
Sanofi
ClinicalTrials.gov Identifier:
NCT00445302
First received: March 7, 2007
Last updated: February 10, 2014
Last verified: February 2014

March 7, 2007
February 10, 2014
January 2006
August 2007   (final data collection date for primary outcome measure)
  • Dose-Normalized Maximum Concentration of Plerixafor (Cmax) [ Time Frame: Pre-dose of plerixafor to 24 hours post-plerixafor ] [ Designated as safety issue: No ]
    Evaluation of Cmax following a single dose of 240 µg/kg plerixafor administered on Day 1. Cmax was normalized by dose.
  • Dose-Normalized Area Under the Plerixafor Concentration Time Curve From Time 0 to 24 Hours Post-dose (AUC0-24h) [ Time Frame: Pre-dose of plerixafor to 24 hours post-plerixafor ] [ Designated as safety issue: No ]
    Evaluation of AUC0-24 hour following a single dose of 240 µg/kg plerixafor administered on Day 1. AUC0-24 was normalized by dose.
To determine the effects of impaired renal function on the pharmacokinetics of 240 μg/kg SC dose of AMD3100.
Complete list of historical versions of study NCT00445302 on ClinicalTrials.gov Archive Site
  • Change From Baseline in Absolute CD34+ Cell Counts at Day 2 [ Time Frame: Baseline, Day 2 ] [ Designated as safety issue: No ]
    Change in circulating CD34+ cells from baseline to Day 2 (24 hours post-plerixafor) following a single dose of plerixafor. Change from baseline = CD34+ cell count at 24 hours post dose - CD34+ cell count at Baseline.
  • Change From Baseline in Absolute White Blood Cell (WBC) Counts at Day 2 [ Time Frame: Baseline and Day 2 ] [ Designated as safety issue: No ]
    Change in absolute white blood cells from baseline to Day 2 (24 hours post-plerixafor) following a single dose of plerixafor. Change from baseline = absolute white blood cells at 24 hours post dose - absolute white blood cells at Baseline.
  • Number of Participants in Overall Safety Summary of Adverse Events (TEAE) [ Time Frame: up to Day 3 ] [ Designated as safety issue: Yes ]
    Number of participants with adverse events (AEs) collected from Day 1 (post plerixafor administration) to Day 3. AEs were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for severity (mild, moderate, severe, life-threatening) and relatedness to study treatment (5 point scale from 'not related' to 'definitely related').
  • To determine whether impaired renal function alters the hematological effect of a 240 µg/kg SC dose of AMD3100 on circulating WBCs and CD34+ cells and whether this effect is independent of changes in AMD3100 PK
  • to evaluate the safety of a 240µg/kg subcutaneous dose of AMD3100 administered to subjects with renal impairment.
Not Provided
Not Provided
 
Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment
A Phase I Study Of The Safety, Pharmacokinetics, And Hematological Activity Of AMD3100 (240 µg/kg) In Subjects With Renal Impairment

Eligible male and female subjects with renal impairment (aged 18-78 years) and healthy control subjects (aged 35 to 78 years) will be enrolled in the study. Subjects with renal impairment will be enrolled and entered into three groups based on their renal function: Mild Impairment, Moderate Impairment, and Severe Impairment(not requiring dialysis). Control subjects will have normal renal function.

The screening visits will occur within 14 days prior to plerixafor administration on study day one. Subjects will be monitored for 10 hours following administration of the study drug. In addition, subjects will return to the clinic at 24 and 48 hours after plerixafor administration for blood samples and safety assessments.

This is a phase I, open label, multi-center study in which up to eighteen subjects with renal impairment and six healthy control subjects with normal renal function will receive a single dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.

Eligible male and female subjects with renal impairment (aged 18-78 years) and healthy control subjects (aged in the upper age range of the renal impairment subjects) will be enrolled in the study. Subjects with renal impairment will be enrolled and stratified into three cohorts using their Screening 24 hour urine collection to measured creatinine clearance (CLcr) values (an estimate of Glomerular Filtration Rate): Mild Impairment (CLcr = 51-80 ml/min), Moderate Impairment (CLcr = 31-50 ml/min), and Severe Impairment (CLcr <31 ml/min, not requiring dialysis). Control subjects will have normal renal function (CLcr >90 ml/min), as determined by a Screening 24 hour urine collection.

The screening visits will occur within 14 days prior to plerixafor administration on study day one. Subjects will be monitored for 10 hours following administration of the study drug. In addition, subjects will return to the clinic at 24 and 48 hours after plerixafor administration for blood samples and safety assessments.

This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Renal Impairment
Drug: plerixafor
Single dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection
Other Names:
  • Mozobil
  • AMD3100
  • Active Comparator: Normal renal function
    Participants with normal renal function (creatinine clearance (CLcr) > 90 ml/min) who serve as the study control. Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
    Intervention: Drug: plerixafor
  • Experimental: Mild renal impairment
    Participants have mild renal impairment (creatinine clearance (CLcr) = 51 to 80 mL/min). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
    Intervention: Drug: plerixafor
  • Experimental: Moderate renal impairment
    Participants have moderate renal impairment (creatinine clearance (CLcr) = 31 to 50 mL/min). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
    Intervention: Drug: plerixafor
  • Experimental: Severe renal impairment
    Participants have severe renal impairment (creatinine clearance (CLcr) < 31 mL/min, not requiring dialysis). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
    Intervention: Drug: plerixafor
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
23
August 2007
August 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Signed patient informed consent form prior to any study procedures at Screening.
  • Subject has not consumed alcohol in the 48 hours prior to the administration of study drug.
  • Subject agrees to refrain from consumption of alcohol for the duration of the trial.
  • Subject agrees to practice an approved method of contraception for the duration of the study.
  • White blood cell count ≧3.5*10^9/L.
  • Absolute polymorphonuclear leukocyte count >2.5*10^9/L.
  • Platelet count >125*10^9/L.
  • Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) and total bilirubin <2 times upper limit of normal (ULN).
  • Negative for Human Immunodeficiency Virus (HIV).
  • Age: Renal impairment subjects, 18-78 years. Control subjects, 35-78 years.
  • Creatinine clearance measured from 24-hour urine collection (CLcr u): Renal impairment cohorts, Mild Impairment (CLcr u = 51-80 ml/min), Moderate Impairment (CLcr u = 31-50 ml/min), and Severe Impairment (CLcr u <31 ml/min, not requiring dialysis). Control subjects, CLcr u >90 ml/min.

Exclusion Criteria:

  • Known sensitivity to plerixafor or any of its components.
  • Pregnant or breast-feeding.
  • Actual body weight exceeds 175% of ideal body mass index.
  • Subjects judged by the investigator to be at significant risk of failing to comply with the requirements of the protocol.
  • Any subject who has started new medication within 14 days prior to study drug administration.
  • Treatment with an investigational product within 30 days prior to trial entry.
  • Any significant untreated or newly diagnosed medical condition other than renal impairment that in the opinion of the investigator may interfere with the conduct of the study.
  • Abnormal electrocardiogram with clinically significant rhythm disturbance,(ventricular arrhythmias), or other conduction abnormality that in the opinion of the investigator warrants exclusion of the subject from the trial.
  • History of clinically significant thrombocytopenia.
  • Received blood transfusions within 30 days prior to trial entry.
  • Any subject who requires therapeutic intervention within the 30 days prior to administration of study medication in order to meet the inclusion/exclusion criteria.
  • Active malignant/neoplastic disease requiring treatment of any kind.
  • Active infection requiring antibiotics
  • Renal impairment requiring any method of dialysis
  • History of kidney transplant
  • Subjects having clinical status or laboratory parameter deterioration between the time of enrollment and dosing with plerixafor (such that they no longer meet entry criteria) may be removed from the study at the discretion of the treating physician, principal investigator, or sponsor.
Both
18 Years to 78 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00445302
AMD31001101
No
Medical Monitor, Genzyme
Genzyme, a Sanofi Company
Not Provided
Study Director: Medical Monitor Genzyme, a Sanofi Company
Sanofi
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP